Business Context and Reporting Period
This Form 8-K is a current report filed by CytomX Therapeutics, Inc. on July 12, 2017. The filing addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Dismissal of Auditor: On July 12, 2017, the Audit Committee dismissed PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm.
- Appointment of New Auditor: On July 12, 2017, the Audit Committee appointed Ernst & Young LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Audit History: PwC's reports for fiscal years 2015 and 2016 were unqualified and contained no adverse opinions or disclaimers.
- Disagreements: There were no disagreements with PwC regarding accounting principles, practices, or audit scope during the relevant periods.
- Reportable Events: No "reportable events" occurred during the tenure of PwC or the interim period leading up to the dismissal.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business operations. It confirms that the company has not consulted with the new auditor, Ernst & Young, regarding accounting principles or audit opinions prior to their appointment.
Investor Verification Checklist
- Verify the content of the letter from PricewaterhouseCoopers LLP (Exhibit 16.1) to confirm their agreement with the company's statements regarding the dismissal.
- Review the company's most recent 10-K or 10-Q filings to assess the financial health and cash runway, as this 8-K contains no financial data.
- Monitor future filings for the transition of audit responsibilities and any potential restatements or changes in accounting policies under the new firm.